Topikal Retinoidler: Adapalen
Özet
Adapalen, akne vulgaris tedavisi için FDA tarafından onaylanmış topikal retinoiddir. Tretinoin ve diğer topikal retinoidlerle yapılan karşılaştırmalı çalışmalarda hafif ve orta şiddetteki akne lezyonlarında özellikle komedolar üzerinde etkisi gösterilmiş, yan etki profili en düşük topikal retinoid olarak bulunmuştur. Keratinizasyonu düzenleyici, antinflamatuvar ve tirozinaz inhibisyonu gibi etkileri ile aknede skar gelişiminin ve postinflamatuvar hiperpigmentasyonun önlenmesi için de başarılı olduğu gösterilmiştir.
Referanslar
Brogden RN, Goa KL. Adapalene: A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs 1997; 53:511-519.
Tolaymat L, Zito PM. Adapalene. NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Sept 29.
Şanlı H, Kalay Yıldızhan İ. Topikal tedaviler. Türkderm 2020;54 (Suppl 1) :23-9.
Saurat JH, Sorg O. Retinoids. İn Callaen JP Cawen EW, Hruza GJ et all eds. Bolognia JL, Schaffer JV, Cerroni L Dermatology. 4 th edn, Elsevier, China, e book. 2018; Vol2:2200.
Ertekin SS, Gürel MS. Mechanism of action of Topical Retinoids. İn Karadag AS, Aksoy B, Parish LC eds. Retinoids in Dermatology. First Edn. CRC press. Boca Raton, London, New York 2020:7.
Tolaymat L, Zito PM. Adapalene. NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Sept 29.
Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with Adapalene gel 0.1%. J Eur Acad Dermatol Venereol 2007; 21:747-53.
Shroot B, Michel S. Pharmacology of retinoids in the skin: In vitro and in vivo assays. Eur J Med Chem 1995;30 Suppl:487-503.
Tenaud I, Khammari A, Dreno B. In vitro modulation of TLR-2, CD1d and I-10 by Adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol. 2007; 16:500-506.
Ramezanli T, Michniak-Kohn BB. Development and characterization of a topical gel formulation of Adapalene-TyroSpheres and assessment of its clinical efficacy. Mol Pharm. 2018;15(9):3813-3822.
Phillips TJ. An update on the safety and efficacy of topical retinoids. Cutis 2005; 75:14-22.
Jacky AK, Mpofu P. Adapalene 0.1% for topical treatment of acne vulgaris in African patients. Cutis 2001; 68:48-54.
Tan J, Miklas M. A Novel Topical Retinoid for Acne: Trifarotene 50 μg/g Cream. Skin Therapy Lett 2020;25(2):1-2.
Stein Gold LF, Alexis AF, Harper JC, Tan JKL. Advances in acne and rosacea therapy. Semin Cutan Med Surg. 2018;37(3S): S63-S66.
Tan J, Bissonnette R, Gratton D, Kerrouche N, Canosa JM. The safety and efficacy of four different fixed combination regimens of Adapalene 0.1%/benzoyl peroxide 2.5% gel for the treatment of acne vulgaris: results from a randomised controlled study. Eur J Dermatol. 2018;28(4):502-508.
Bagatin E, Gonçalves HS, Sato M, Almeida LMC, Miot HA. Comparable efficacy of Adapalene 0.3% gel and tretinoin 0.05% cream as treatment for cutaneous photoaging. Eur J Dermatol. 2018; 28(3):343-350.
Thiboutot DM, Dréno B, Abanmi A, Alexis AF, Araviiskaia E, Barona Cabal MI, et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2018;78(Suppl 1): S1-S23.
Dréno B, Bissonnette R, Gagné-Henley A, Barankin B, Lynde C, Chavda R, et al. Long-Term Effectiveness and Safety of Up to 48 Weeks' Treatment with Topical Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in the Prevention and Reduction of Atrophic Acne Scars in Moderate and Severe Facial Acne. Am J Clin Dermatol. 2019;20(5):725-732.
Treesirichod A, Chaithirayanon S, Wongjitrat S. Comparison of the efficacy and safety of 0.1% Adapalene gel and 0.025% tretinoin cream in the treatment of childhood acanthosis nigricans. Ped Dermatol 2019; 36:330-334.
Tanghetti E, Dhawan S, Green L, Del Rosso J, Draelos Z, Leyden J, Shalita A, et al. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol. 2010;9(5):549-58.
Li H, Wang C, Li L, Bu W, Zhang M, Wei J, et al. Adapalene suppressed the proliferation of melanoma cells by S-phase arrest and subsequent apoptosis via induction of DNA damage. Eur J Pharm 2019; 851:174-185.
Bouclier M, Chatelus A, Verschoore M. Quantification of epidermal histological changes induced by topical adapalene %0,1 gel in the rhino mouse model using a standardized image analysis technique (abstract) Br J Dermatol 1996; 135suppl.47:29.
Thiboutot D, Gold MH, Jarratt MT, Kang S, Kaplan DL, Millikan L, et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis. 2001; 68(4 Suppl):10-9.
Cunliffe WJ, Danby FW, Dunlap F, Gold MH, Gratton D, Greenspan A: Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol 2002; 12:350-4.
Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Arsonnaud S, Kang S; Differin Study Group. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed. 2005;4(3):138-46.
Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1%gel versus tretinoin 0.0025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998;139(Suppl52):48-56.
Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open – labell clinical trial. Br J Dermatol 2002; 147:521-527.
Thiboutot D, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. J Drug Dermatol 2008;7(6 Suppl):3-10.
Pariser D, Colon LE, Johnson LA, Gottschalk RW. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris. J Drug Dermatol 2008; 7(6 Suppl):18-23.
Gollnick HP, Draelos Z, Glenn MJ, Rosoph LA, Kaszuba A, Cornelison R, et al; Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol. 2009;161(5):1180-9.
Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, et al; Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007;57(5):791-9.
Hayashi N, Akamatsu H, Iwatsuki K, Shimada-Omori R, Kaminaka C, Kurokawa I,. Japanese Dermatological Association Guidelines: Guidelines for the treatment of acne vulgaris 2017. J Dermatol. 2018;45(8):898-935.
Stein Gold L, Baldwin HE, Lin T. Management of severe acne vulgaris with topical therapy. J Drugs Dermatol. 2017;16(11):1134-1138.
Webster GF, Guenther L, Poulin YP, Solomon BA, Loven K, Lee J: A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis 2002;69(Suppl 2):4-11.
Adapalene. Drugs and Lactation Database. (LactMed). – NCBI Bookshelf. Last Revision: October 31, 2018.
Topical retinoids during pregnancy (continued). Prescrire Int. 2005;14(77):100-1.
